Illustrative image.
Actemra
Tocilizumab
$3300.00
162mg · 3 × 4 pre-filled syringe · 3 months supply
BrandBranded medicine· By Roche
$1100.00 per month
How long a supply?
Test mode: no payment is taken. View cart
Ships cold, in insulated packing
This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.
Annual cost
$14300a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningRisk of serious infections
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
If a serious infection develops, interrupt ACTEMRA until the infection is controlled.
Reported infections include:
Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients, except those with COVID-19, should be tested for latent tuberculosis before ACTEMRA use and during therapy. Treatment for latent infection should be initiated prior to ACTEMRA use.
Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
Bacterial, viral and other infections due to opportunistic pathogens.
The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ACTEMRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.
Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic infections have occurred in patients receiving ACTEMRA.
Perform test for latent TB (except patients with COVID-19); if positive, start treatment for TB prior to starting ACTEMRA.
Monitor all patients for active TB during treatment, even if initial latent TB test is negative.
About Actemra
Overview
Actemra (tocilizumab) is a prescription monoclonal antibody medicine available as a pre-filled syringe or auto-injector. It is used in adults to treat moderately to severely active rheumatoid arthritis when one or more disease-modifying medicines have not worked well enough, to treat giant cell arteritis, and to slow lung function decline in systemic sclerosis-associated interstitial lung disease. It also treats active polyarticular or systemic juvenile idiopathic arthritis in patients aged 2 years and older. It works by blocking receptors for interleukin-6 (IL-6), a substance involved in inflammation.
What it treats
Moderately to severely active rheumatoid arthritis in adults whose condition has not responded adequately to one or more disease-modifying antirheumatic drugs (DMARDs). Giant cell arteritis in adults. Systemic sclerosis-associated interstitial lung disease in adults, to slow the decline in lung function. Active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older. Active systemic juvenile idiopathic arthritis in patients aged 2 years and older. Severe or life-threatening cytokine release syndrome caused by CAR T-cell treatment in patients aged 2 years and older. COVID-19 in hospitalized patients aged 2 years and older who are receiving systemic corticosteroids and need supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Safety information
Side effects
Common side effects include upper respiratory tract infections, nose and throat inflammation, headache, high blood pressure, increased levels of the liver enzyme ALT, and injection-site reactions. Serious side effects include serious infections, gastrointestinal perforation (a hole in the stomach or bowel), liver injury, and severe allergic reactions, including anaphylaxis, which can be fatal. Serious skin reactions can also occur, including DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). Contact a doctor immediately if you develop or suspect any of these reactions. Actemra can also change neutrophil (a type of white blood cell) and platelet counts, blood fat levels, and liver function test results. Blood tests are recommended to monitor these changes. Disorders affecting the protective covering of nerves are also listed as serious adverse reactions.
FDA boxed warning
Risk of serious infections
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
If a serious infection develops, interrupt ACTEMRA until the infection is controlled.
Reported infections include:
Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients, except those with COVID-19, should be tested for latent tuberculosis before ACTEMRA use and during therapy. Treatment for latent infection should be initiated prior to ACTEMRA use.
Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
Bacterial, viral and other infections due to opportunistic pathogens.
The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ACTEMRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.
Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic infections have occurred in patients receiving ACTEMRA.
Perform test for latent TB (except patients with COVID-19); if positive, start treatment for TB prior to starting ACTEMRA.
Monitor all patients for active TB during treatment, even if initial latent TB test is negative.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not use Actemra if you have a known allergy to it. It must not be given during an active infection, including an infection limited to one area. If a serious infection develops, treatment must be paused until the infection is controlled. Caution is needed if you are at increased risk of a tear in the stomach or bowel wall. Actemra can cause liver injury and changes in white blood cells called neutrophils, platelets, cholesterol and other blood fats. Blood tests are needed to monitor these effects. Persistent or worsening liver test abnormalities, or signs of liver disease, may require treatment changes or stopping Actemra. Severe allergic reactions, including potentially fatal anaphylaxis, and serious skin reactions such as DRESS can occur. If these develop, stop Actemra and seek urgent medical attention. Avoid live vaccines during treatment. Actemra may harm an unborn baby based on animal studies. If you are pregnant or breastfeeding, discuss treatment with your prescriber. A decision is needed about whether to stop Actemra or breastfeeding, taking into account the importance of treatment to the mother.
Using Actemra
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton to protect it from light. Check the pack for whether it must be refrigerated before first use. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label ACTEMRA (TOCILIZUMAB) INJECTION, SOLUTION, CONCENTRATE ACTEMRA (TOCILIZUMAB) INJECTION, SOLUTION ACTEMRA ACTPEN (TOCILIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Firazyr
Icatibant (as Acetate)
By Takeda
Pre-Filled Syringe · from 1 per pack
Also for immune system
Brand $3,070.00
Orladeyo
Berotralstat
By BioCryst Pharmaceuticals
Capsules · from 28 per pack
Also for immune system
Brand $26,075.00
Rezurock
Belumosudil
By Sanofi
Tablets · from 30 per pack
Also for immune system
Brand $17,390.00
Olumiant
Baricitinib
By Lilly
Tablets · from 14 per pack
Also for immune system
Brand from $330.00